Altered Blood-Brain Barrier Dynamics in the C9orf72 Hexanucleotide Repeat Expansion Mouse Model of Amyotrophic Lateral Sclerosis

For peripherally administered drugs to reach the central nervous system (CNS) and treat amyotrophic lateral sclerosis (ALS), they must cross the blood-brain barrier (BBB). As mounting evidence suggests that the ultrastructure of the BBB is altered in individuals with ALS and in animal models of ALS...

Full description

Saved in:
Bibliographic Details
Main Authors: Yijun Pan (Author), Yoshiteru Kagawa (Author), Jiaqi Sun (Author), Bradley J. Turner (Author), Cheng Huang (Author), Anup D. Shah (Author), Ralf B. Schittenhelm (Author), Joseph A. Nicolazzo (Author)
Format: Book
Published: MDPI AG, 2022-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ce792643f94e4e4a96edfc45439b2c0c
042 |a dc 
100 1 0 |a Yijun Pan  |e author 
700 1 0 |a Yoshiteru Kagawa  |e author 
700 1 0 |a Jiaqi Sun  |e author 
700 1 0 |a Bradley J. Turner  |e author 
700 1 0 |a Cheng Huang  |e author 
700 1 0 |a Anup D. Shah  |e author 
700 1 0 |a Ralf B. Schittenhelm  |e author 
700 1 0 |a Joseph A. Nicolazzo  |e author 
245 0 0 |a Altered Blood-Brain Barrier Dynamics in the C9orf72 Hexanucleotide Repeat Expansion Mouse Model of Amyotrophic Lateral Sclerosis 
260 |b MDPI AG,   |c 2022-12-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics14122803 
500 |a 1999-4923 
520 |a For peripherally administered drugs to reach the central nervous system (CNS) and treat amyotrophic lateral sclerosis (ALS), they must cross the blood-brain barrier (BBB). As mounting evidence suggests that the ultrastructure of the BBB is altered in individuals with ALS and in animal models of ALS (e.g., SOD1<sup>G93A</sup> mice), we characterized BBB transporter expression and function in transgenic C9orf72 BAC (C9-BAC) mice expressing a hexanucleotide repeat expansion, the most common genetic cause of ALS. Using an in situ transcardiac brain perfusion technique, we identified a 1.4-fold increase in <sup>3</sup>H-2-deoxy-D-glucose transport across the BBB in C9-BAC transgenic (C9) mice, relative to wild-type (WT) mice, which was associated with a 1.3-fold increase in brain microvascular glucose transporter 1 expression, while other general BBB permeability processes (passive diffusion, efflux transporter function) remained unaffected. We also performed proteomic analysis on isolated brain microvascular endothelial cells, in which we noted a mild (14.3%) reduction in zonula occludens-1 abundance in C9 relative to WT mice. Functional enrichment analysis highlighted trends in changes to various BBB transporters and cellular metabolism. To our knowledge, this is the first study to demonstrate altered BBB function in a C9orf72 repeat expansion model of ALS, which has implications on how therapeutics may access the brain in this mouse model. 
546 |a EN 
690 |a amyotrophic lateral sclerosis 
690 |a blood-brain barrier 
690 |a brain microvascular endothelial cells 
690 |a C9orf72 gene 
690 |a proteomics 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 14, Iss 12, p 2803 (2022) 
787 0 |n https://www.mdpi.com/1999-4923/14/12/2803 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/ce792643f94e4e4a96edfc45439b2c0c  |z Connect to this object online.